Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
Fortrea Holdings Inc. (FTRE)
Company Research
Source: GlobeNewswire
Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure-play contract research organization Creates standalone best-in-class Randomization and Trial Supply Management and Patient Access solutions positioned for differentiation and growth DURHAM, N.C., March 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing in building market-leading, technology-rich healthcare companies. By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the
Show less
Read more
Impact Snapshot
Event Time:
FTRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FTRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FTRE alerts
High impacting Fortrea Holdings Inc. news events
Weekly update
A roundup of the hottest topics
FTRE
News
- Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference CallGlobeNewswire
- Fortrea Announces Date for First Quarter 2024 Financial Results and Conference CallGlobeNewswire
- Fortrea Holdings Inc. (NASDAQ: FTRE) is now covered by analysts at Robert W. Baird. They set a "neutral" rating and a $43.00 price target on the stock.MarketBeat
- Fortrea Reports Fourth Quarter and Full-Year 2023 Results; Issues Full-Year 2024 GuidanceGlobeNewswire
- Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ ExpansionGlobeNewswire
FTRE
Earnings
- 3/11/24 - Miss
FTRE
Sec Filings
- 4/1/24 - Form 8-K
- 3/28/24 - Form ARS
- 3/28/24 - Form DEFA14A
- FTRE's page on the SEC website